



October 30, 2017

Five Prime Therapeutics Presents Preclinical Data Demonstrating Potent Anti-Tumor Activity with FPT155

- | *Poster featured at 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics*
- | *Company anticipates filing an IND for FPT155 in mid 2018*

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2017 (GLOBE NEWSWIRE) -- [Five Prime Therapeutics, Inc.](#) (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, announced today that new preclinical data demonstrating potent anti-tumor activity with [FPT155](#), its novel therapeutic CD80-Fc fusion protein, were featured in a poster presentation yesterday during the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The conference is being held October 26-30, 2017, in Philadelphia. A PDF of the poster, "FPT155, a novel therapeutic CD80-Fc fusion protein, with potent anti-tumor activity in preclinical models," will be made available on the [Publications](#) page of the Five Prime website.

"The work done in preclinical models with FPT155 suggests that it has the potential to be a potent T cell co-stimulator with strong antitumor activity, and it may have a synergistic effect when combined with anti-PD1 therapy," said Bryan Irving, Ph.D., Senior Vice President of Research at Five Prime. "These results are very encouraging, and we are working to complete IND-enabling studies in anticipation of an IND filing for FPT155 in mid 2018."

Five Prime has developed FPT155, a novel CD80 (B7.1) extracellular domain (ECD)-Fc fusion protein, as a co-stimulatory molecule designed to stimulate T cell activation and break tumor immune tolerance. In vitro studies show that FPT155 induces T cell activation and cytokine production via CD28, but is dependent on co-engagement of the T cell antigen receptor, differentiating it from a CD28 "superagonist." A murine FPT155 was generated to investigate FPT155's impact in preclinical models and was found to be well tolerated with potent efficacy in syngeneic tumor models, including the induction of complete tumor regression in the CT26 model. mFPT155 promotes the infiltration of T cells into the tumor core and increases the ratio of effector T cells to regulatory T cells, thus inducing a favorable microenvironment for an effective antitumor immune response. Furthermore, in preclinical studies combination of mFPT155 and anti-PD1 therapy leads to stronger antitumor efficacy compared to either therapy alone.

About Five Prime

Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and late preclinical development. For more information, please visit www.fiveprime.com.

Cautionary Note on Forward-looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Five Prime's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements about the timing of the filing of an IND for the FPT155 program. Many factors may cause differences between current expectations and actual results including unexpected safety or efficacy data observed during preclinical studies, unexpected delays in manufacturing activities and delays in establishment of necessary contractual relationships. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Five Prime's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" contained therein. Except as required by law, Five Prime assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

CONTACT:

Derek Cole
Investor Relations Advisory Solutions
720-785-4497
derek.cole@iradvisory.com

Source: Five Prime Therapeutics, Inc.

News Provided by Acquire Media